Filing Flows › West Pharmaceutical Services (WST) › Gross margin
West Pharmaceutical Services (WST) gross margin by quarter
West Pharmaceutical Services' gross margin was 39.7% in Q3 2026 (third quarter 2026), +2.0 pts from Q2 2026. Over the last 7 quarters it ranged from 33.2% (Q1 2025) to 39.7% (Q3 2026).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 39.7% | +2.0 pts | +3.1 pts |
| Q2 2026 | 37.7% | +2.7 pts | +2.0 pts |
| Q1 2026 | 35.1% | -2.7 pts | +1.9 pts |
| Q4 2025 | 37.8% | +1.2 pts | — |
| Q3 2025 | 36.6% | +0.8 pts | — |
| Q2 2025 | 35.7% | +2.5 pts | — |
| Q1 2025 | 33.2% | — | — |
Q3 2026 at a glance
West Pharmaceutical Services, Q3 2026: revenue $874M (+9% year over year), operating margin 30.6%, net earnings $214M, operating cash flow $190M. The chart follows the revenue to costs, profit and cash.
Questions
What is West Pharmaceutical Services' gross margin?
West Pharmaceutical Services' gross margin was 39.7% in Q3 2026 (third quarter 2026), +2.0 pts from Q2 2026.
How has West Pharmaceutical Services' gross margin changed?
Over the last 7 quarters it ranged from 33.2% (Q1 2025) to 39.7% (Q3 2026).
Q3 2026 results → · How West Pharmaceutical Services makes money →